Novartis and Legend Biotech Sign Exclusive License Agreemenhttps://www.biopharminternational.com/view/novartis-and-legend-biotech-sign-exclusive-license-agreement-for-car-t-therapies
CAR-T stuff is heating up again. Novartis T-Charge is an in vivo therapy which could be a game changer in my opinion.
It's a Phase one but if others are paying attention it could spur interest in Pelareorep. Just not sure where our BD is on CAR-T so far unfortunately. Novartis will be targeting solid Tumors with It's T-Charge platform.
Novartis may also apply its T-Charge CAR-T cell therapy platform to the manufacture of these candidates. The platform is a next-generation CAR-T cell therapy manufacturing platform designed to preserve T cell stemness. It also facilitates CAR-T cell expansion primarily in vivo. The platform is designed to reduce the need for extensive culture time outside the body and results in T cells with greater proliferative potential as well as fewer exhausted T cells. If applied to the manufacture of LB2102, this would be the first application of the T-Charge platform to a cell therapy candidate targeting solid tumors, according to a company press release.
Cheers!!!!!!!!!!!!!!!!!